Potential	potential	O	O	O	O
therapeutic	therapeutic	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
selective	selective	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
D1	d1	O	O	O	O
receptor	receptor	O	O	O	O
agonist	agonist	O	O	O	O
,	,	O	O	O	O
A-86929	a-86929	O	O	OTHERS	I
:	:	O	O	O	O
an	an	O	O	O	O
acute	acute	O	O	O	O
study	study	O	O	O	O
in	in	O	O	O	O
parkinsonian	parkinsonian	O	DISEASE	OTHERS	I
levodopa-primed	levodopa-primed	O	O	O	O
monkeys	monkeys	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
clinical	clinical	O	O	O	O
utility	utility	O	O	O	O
of	of	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
DA	da	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
D1	d1	O	O	O	O
receptor	receptor	O	O	O	O
agonists	agonists	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
(	(	O	O	O	O
PD	pd	O	DISEASE	OTHERS	I
)	)	O	O	O	O
is	is	O	O	O	O
still	still	O	O	O	O
unclear	unclear	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
therapeutic	therapeutic	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
selective	selective	O	O	O	O
DA	da	CHEMICALS	O	OTHERS	I
D1	d1	O	O	O	O
receptor	receptor	O	O	O	O
agonists	agonists	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
SKF-82958	skf-82958	O	O	OTHERS	I
(	(	O	O	O	O
6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze	6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzaze	O	O	OTHERS	I
pine	pine	O	O	OTHERS	I
hydrobromide	hydrobromide	O	O	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
A-77636	a-77636	O	O	OTHERS	I
(	(	O	O	O	O
[	[	O	O	OTHERS	I
1R	1r	O	O	OTHERS	I
,	,	O	O	OTHERS	I
3S	3s	O	O	OTHERS	I
]	]	O	O	OTHERS	I
3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo	3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1h-2-benzo	O	O	OTHERS	I
pyran	pyran	O	O	OTHERS	I
hydrochloride	hydrochloride	O	O	OTHERS	I
)	)	O	O	O	O
seems	seems	O	O	O	O
limited	limited	O	O	O	O
because	because	O	O	O	O
of	of	O	O	O	O
their	their	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
action	action	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
is	is	O	O	O	O
too	too	O	O	O	O
short	short	O	O	O	O
for	for	O	O	O	O
SKF-82958	skf-82958	O	O	OTHERS	I
(	(	O	O	O	O
<	<	O	O	O	O
1	1	O	O	O	O
hr	hr	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
too	too	O	O	O	O
long	long	O	O	O	O
for	for	O	O	O	O
A-77636	a-77636	O	O	OTHERS	I
(	(	O	O	O	O
>	>	O	O	O	O
20	20	O	O	O	O
hr	hr	O	O	O	O
,	,	O	O	O	O
leading	leading	O	O	O	O
to	to	O	O	O	O
behavioral	behavioral	O	O	O	O
tolerance	tolerance	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
therefore	therefore	O	O	O	O
conducted	conducted	O	O	O	O
the	the	O	O	O	O
present	present	O	O	O	O
acute	acute	O	O	O	O
dose-response	dose-response	O	O	O	O
study	study	O	O	O	O
in	in	O	O	O	O
four	four	O	O	O	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	O	O	OTHERS	I
(MPTP)-exposed	(mptp)-exposed	O	O	O	O
cynomolgus	cynomolgus	O	O	O	O
monkeys	monkeys	O	O	O	O
primed	primed	O	O	O	O
to	to	O	O	O	O
exhibit	exhibit	O	O	O	O
levodopa-induced	levodopa-induced	O	O	O	O
dyskinesias	dyskinesias	O	DISEASE	OTHERS	I
to	to	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
locomotor	locomotor	O	O	O	O
and	and	O	O	O	O
dyskinetic	dyskinetic	O	O	OTHERS	I
effects	effects	O	O	O	O
on	on	O	O	O	O
challenge	challenge	O	O	O	O
with	with	O	O	O	O
four	four	O	O	O	O
doses	doses	O	O	O	O
(	(	O	O	O	O
from	from	O	O	O	O
0.03	0.03	O	O	O	O
to	to	O	O	O	O
1.0	1.0	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
A-86929	a-86929	O	O	OTHERS	I
(	(	O	O	O	O
[-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+	[-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+	O	O	O	O
+	+	O	O	O	O
+	+	O	O	O	O
azacyclopent-1-	azacyclopent-1-	O	O	O	O
ena[c]phenathrene-9	ena[c]phenathrene-9	O	O	O	O
-	-	O	O	O	O
10-diol	10-diol	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
selective	selective	O	O	O	O
and	and	O	O	O	O
full	full	O	O	O	O
DA	da	CHEMICALS	O	OTHERS	I
D1-like	d1-like	O	O	O	O
receptor	receptor	O	O	O	O
agonist	agonist	O	O	O	O
with	with	O	O	O	O
an	an	O	O	O	O
intermediate	intermediate	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
action	action	O	O	O	O
.	.	O	O	O	O

Levodopa	levodopa	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
the	the	O	O	O	O
DA	da	CHEMICALS	O	OTHERS	I
D2-like	d2-like	O	O	O	O
receptor	receptor	O	O	O	O
agonist	agonist	O	O	O	O
,	,	O	O	O	O
LY-171555	ly-171555	O	O	OTHERS	I
(	(	O	O	O	O
[4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo	[4ar-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2h-pyrazo	O	O	O	O
lo-3	lo-3	O	O	O	O
-	-	O	O	O	O
4-quinoline	4-quinoline	O	O	O	O
hydrochloride	hydrochloride	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
also	also	O	O	O	O
used	used	O	O	O	O
for	for	O	O	O	O
comparison	comparison	O	O	O	O
.	.	O	O	O	O

Acute	acute	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
A-86929	a-86929	O	O	OTHERS	I
was	was	O	O	O	O
as	as	O	O	O	O
efficacious	efficacious	O	O	O	O
in	in	O	O	O	O
alleviating	alleviating	O	O	O	O
MPTP-induced	mptp-induced	O	O	O	O
parkinsonism	parkinsonism	O	DISEASE	OTHERS	I
as	as	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
LY-171555	ly-171555	O	O	OTHERS	I
,	,	O	O	O	O
but	but	O	O	O	O
was	was	O	O	O	O
less	less	O	O	O	O
likely	likely	O	O	O	O
to	to	O	O	O	O
reproduce	reproduce	O	O	O	O
the	the	O	O	O	O
levodopa-induced	levodopa-induced	O	O	O	O
dyskinesias	dyskinesias	O	DISEASE	OTHERS	I
in	in	O	O	O	O
these	these	O	O	O	O
animals	animals	O	O	O	O
than	than	O	O	O	O
with	with	O	O	O	O
either	either	O	O	O	O
LY-171555	ly-171555	O	O	OTHERS	I
or	or	O	O	O	O
subsequent	subsequent	O	O	O	O
challenge	challenge	O	O	O	O
of	of	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Selective	selective	O	O	O	O
stimulation	stimulation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
DA	da	CHEMICALS	O	OTHERS	I
D1	d1	O	O	O	O
receptor	receptor	O	O	O	O
may	may	O	O	O	O
provide	provide	O	O	O	O
better	better	O	O	O	O
integration	integration	O	O	O	O
of	of	O	O	O	O
neural	neural	O	O	O	O
inputs	inputs	O	O	O	O
transmitted	transmitted	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
internal	internal	O	O	O	O
segment	segment	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
globus	globus	O	O	O	O
pallidus	pallidus	O	O	O	O
(	(	O	O	O	O
referred	referred	O	O	O	O
to	to	O	O	O	O
as	as	O	O	O	O
the	the	O	O	O	O
basal	basal	O	O	O	O
ganglia	ganglia	O	O	O	O
output	output	O	O	O	O
)	)	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
selective	selective	O	O	O	O
DA	da	CHEMICALS	O	OTHERS	I
D2	d2	O	O	O	O
receptor	receptor	O	O	O	O
agonist	agonist	O	O	O	O
.	.	O	O	O	O

Potent	potent	O	O	O	O
DA	da	CHEMICALS	O	OTHERS	I
D1	d1	O	O	O	O
receptor	receptor	O	O	O	O
agents	agents	O	O	O	O
with	with	O	O	O	O
an	an	O	O	O	O
intermediate	intermediate	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
efficacy	efficacy	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
A-86929	a-86929	O	O	OTHERS	I
(	(	O	O	O	O
approximately	approximately	O	O	O	O
4	4	O	O	O	O
hr	hr	O	O	O	O
at	at	O	O	O	O
higher	higher	O	O	O	O
doses	doses	O	O	O	O
tested	tested	O	O	O	O
)	)	O	O	O	O
are	are	O	O	O	O
potential	potential	O	O	O	O
therapeutic	therapeutic	O	O	O	O
tools	tools	O	O	O	O
in	in	O	O	O	O
PD	pd	O	DISEASE	OTHERS	I
and	and	O	O	O	O
merit	merit	O	O	O	O
further	further	O	O	O	O
attention	attention	O	O	O	O
.	.	O	O	O	O

